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S t r e s z c z e n i e
Cel pracy: Toczeń rumieniowaty układowy (TRU) jest schorzeniem 
tkanki łącznej o przebiegu układowym. W patogenezie choroby 
uczestniczy kilka genów, spośród których gen p53 odgrywa istot-
ną rolę w kontroli cyklu komórkowego. Celem badania była analiza 
częstości występowania polimorfizmu genu p53 u pacjentów z TRU 
oraz zależności między polimorfizmem genu p53 a cechami klinicz- 
nymi i laboratoryjnymi choroby.
Materiał i  metody: Badanie kliniczno-kontrolne przeprowadzono 
u pacjentów z rozpoznanym TRU w Szpitalu im. Namaziego w Sziraz 
(Iran). Do badania zakwalifikowano 77 pacjentów z rozpoznanym 
TRU – 9 mężczyzn (11,8%) oraz 68 kobiet (88,2%) o średniej wie-
ku 25,61 ±10,69 roku, a także 80 osób zdrowych o średniej wieku 
51,82 ±14,25 roku, tworzących grupę kontrolną. Z kartoteki szpi- 
talnej pozyskano dane uczestników badania, uwzględniając profil 
epidemiologiczny, wywiad chorobowy, objawy schorzenia oraz wy-
niki badań laboratoryjnych. Ekspresję genu p53 oznaczano w lizo-
wanych limfocytach. Uzyskane dane analizowano przy wykorzysta-
niu oprogramowania SPSS w wersji 14.00 dla systemu Windows, 
przyjmując poziom istotności statystycznej jako p < 0,05. 
Wyniki: Częstość występowania genotypów Arg/Arg, Pro/Pro i Arg/
Pro wśród osób zdrowych z grupy kontrolnej wyniosły odpowiednio 
38,8%; 28,8% i 37,5%, natomiast w grupie pacjentów z TRU – od-
powiednio 29,2%; 12,3% i 58,5%. Wykazano tym samym większą 
zależność między chorobą a postacią heterozygotyczną badane-
go polimorfizmu niż występowaniem alleli homozygotycznych. 
Stwierdzono istotną zależność między różnymi typami alleli genu 
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S u m m a r y
Aim: Systemic lupus erythematosus (SLE) is a systemic vasculitic 
disorder, with multiple genes involved in the disease pathogenesis. 
The p53 gene plays an important role in controlling the cell cycle. 
We aimed to study the prevalence of p53 polymorphism in SLE pa-
tients and analyze the relationship between the p53 polymorphism 
and clinical-laboratory features of the disease.
Material and methods: This case-control study was conducted 
on patients with confirmed SLE at Namazi Hospital, Shiraz, Iran. 
Seventy-seven patients with SLE including 9 (11.8%) men and 
68 (88.2%) women with mean age of 25.61 ±10.69 years and 80 
healthy controls with mean age of 51.82 ±14.25 years were includ-
ed. The patients’ information, including the epidemiological profile, 
disease history, disease symptoms and also the laboratory find-
ings, were extracted from the hospital records. The p53 expression 
was determined in lyzed lymphocytes. The data were analyzed us-
ing SPSS software version 14.00 for Windows considering p < 0.05 
as statistically significant. 
Results: The frequencies of Arg/Arg, Pro/Pro and Arg/Pro among 
normal controls were 38.8%, 28.8% and 37.5%, respectively, but 
in the patients, Arg/Arg, Pro/Pro and Arg/Pro genotypes fre-
quencies were shown to be 29.2%, 12.3% and 58.5%, respective-
ly. Thus, heterozygous form of this polymorphism was shown 
to be associated with the disease more than the homozygous 
alleles. There was a significant relationship between the differ-
ent allele types of p53 and some clinical features of SLE. There 
was no association between the different allele types and any 
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of the initial manifestations of the disease and the laboratory 
findings, as well. 
Conclusions: In an Iranian population the functional oncoprotein 
of p53 with codon 72 polymorphism may play an important role in 
the pathogenesis and clinical presentation of SLE. 
Introduction
Systemic lupus erythematosus (SLE) is a multisys-
tem autoimmune disease characterized by acute and 
chronic inflammation of various tissues in various or-
gans such as joints, heart, lung, kidneys, skin, etc, which 
leads to tissue damage [1, 2]. 
Various factors including genetic, epigenetic, ethnic, 
immunoregulatory, hormonal, and environmental fac-
tors have been associated with SLE [3–5]. It seems that 
interaction of specific genetic risk factors with various 
environmental factors causes abnormal immune re-
sponses [2, 6, 7]. However, the exact etiology of SLE has 
not yet been identified. 
SLE is a multifactorial disease and in addition to the 
environmental factors multiple genes contribute to the 
development of the disease [8, 9]. Although SLE inheri-
tance does not follow Mendelian inheritance patterns, 
it has a strong genetic basis with heritability estimates 
of more than 66% [10]. Up to now, more than 30 genes 
have been identified that have been associated with SLE 
and contribute to the mechanisms of SLE and predispose 
individuals to SLE [8, 9]. Well-known genetic risk factors 
that contribute to SLE development include genetic vari-
ants of HLA and Fcγ receptor genes, IRF5, STAT4, PTPN22, 
TNFAIP3, BLK, BANK1, TNFSF4 and ITGA [8, 9]. In polygen-
ic inheritance, many genetic variants each with a small 
to moderate effect size contribute to SLE development.
Products of these genes associated with SLE contrib-
ute to key immunologic pathways such as Toll-like recep-
tors, signaling pathways, immune regulation pathways 
and apoptosis [8, 9].
Genetic risk factors have not been totally identified. 
The p53 is one of the candidate genetic risk factors. p53 
controls cell cycle activities leading to apoptosis of auto-
reactive cells, preventing the proliferation and differenti-
ation of these cells. As a result, any mutations in the p53 
gene may cause cancer and autoimmune diseases [11]. 
The p53 suppressor gene has been located on the 
short arm of chromosome 17 in exon 11. DNA damage 
increases p53 expression which subsequently stops 
the cell cycle and repairs DNA or induces cell apoptosis 
[11–15].
Among 14 known polymorphisms of the p53 gene, co-
don 72 polymorphism is the most common polymorphism 
associated with cancer in the general population [16]. 
p53 a niektórymi cechami klinicznymi TRU. Nie potwierdzono nato-
miast związku między różnymi typami alleli a początkowymi obja-
wami choroby ani wynikami badań laboratoryjnych. 
Wniosek: W populacji irańskiej funkcjonalna onkoproteina p53 
z polimorfizmem kodonu 72 może odgrywać ważną rolę w patoge-
nezie i obrazie klinicznym TRU. 
Many studies have evaluated p53 polymorphism 
in which arginine to proline substitution at codon 72 
changes the function of the p53 molecule and predis-
poses the individual to various diseases including can-
cer and autoimmune diseases [17–20]. As there is no 
such information about p53 polymorphism in Iranian 
patients with SLE, this study aimed to investigate the 
p53 polymorphism in SLE patients and evaluate the re-
lationship between p53 and clinical and laboratory fea-
tures of the disease.
Material and methods
In a case-control study, 77 patients (68 female and 
9 male) with confirmed diagnosis of SLE who were ad-
mitted to Namazi Hospital, affiliated to Shiraz University 
of Medical Sciences, from 2003 to 2005, were included. 
Also, 80 healthy individuals who had been referred to 
the laboratory and gave a blood sample for other rea-
sons were selected as controls.
The information required was extracted from the files 
and by visiting the patients. Informed consent was taken 
from the patients or their parents. The study protocol was 
approved by the ethics committee of the university.
Data including age, gender, onset of symptoms, first 
manifestation of the disease, complications related to 
the involvement of each organ and laboratory findings 
were collected. Then, the prevalence of the patients with 
homozygous or heterozygous polymorphism and the re-
lationship between any of the mentioned parameters 
and the allele type were determined.
Implemented methods
By taking 10 cc of fresh blood, DNA was extracted 
using the salting-out method. The peripheral blood of 
the controls was obtained and DNA was extracted from 
them as well. PCR was performed to determine codon 
72 polymorphism on the p53 gene. One pair of primers 
was designed for each allele separately (Arg and Pro). 
The sequence of forward and reverse primer pairs was 
as follows: 
•	Arg F: TCC CCC TTG CCG TCC CAA, 
•	Arg R: CTG GTG CAG GGG CCA CCC, 
•	Pro F: GCCAGAGGCTGGTCCCCC, 
•	Pro R: CGTGCAAGTCACAGACTT. 
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PCR products were analyzed using 2% agarose gel 
electrophoresis, with ethidium bromide staining, and 
DNA detection was done with a UV transilluminator 
device.
PCR products were 141 bp and 177 bp for arginine 
and the proline containing alleles, respectively. For het-
erozygous samples, both PCR bands appeared while 
only one band of the spectrum appeared for homozy-
gous samples.
Data analysis
The data were analyzed using SPSS software ver-
sion 14.00 for Windows (SPSS Inc., Chicago, IL) and 
the Pearson χ2 test was used for data analysis. P value 
< 0.05 was considered as the statistically significant level.
Results 
Among 77 patients studied with the mean age of 
25.61 ±10.69 years, 9 (11.7%) patients were male and 
68 (88.3%) were female. The mean age at the onset of 
the first symptoms of the disease was 20.65 ±1.27 years. 
Mean age of the control group was 51.82 ±14.25 years 
and all of them were female.
Of 77 patients successful DNA analysis was per-
formed only in 65 patients. The frequency of p53 alleles 
in the patients with SLE was 41.6% for Arg/Pro, 28.6% 
for Arg/Arg and 14.3% for Pro/Pro while in the control 
group the most frequent type of allele was Arg/Arg with 
38.8%; however, the frequency of Arg/Pro and Pro/Pro 
alleles was respectively 37.5% and 23.8%. There was 
a significant difference in the frequency of alleles be-
tween the SLE and control groups (p = 0.03) (Table I).
About 71.9% of the patients had no family history of 
SLE while a positive family history of SLE was found in 
20.9% of the patients; positive family history of other 
rheumatic diseases and cancer in first-degree relatives 
was seen in 7% and 4.7% of the patients, respectively.
Regarding the frequency, the most important initial 
signs and symptoms were fever in 37%, arthritis in 33%, 
arthralgia in 28.4% and malar rash in 22.2% of the pa-
tients (Table II).
Among the lupus criteria for diagnosis, the most 
common findings were renal involvement (82.7%), an-
ti-nuclear antibody (ANA) (81.5%), hematologic mani-
festation (76.5%), malar rash (74.1%), arthritis (72.7%), 
photosensitivity (48.1%), immunologic findings (45.5%), 
oral ulcer (38.3%), neurologic manifestations (seizures 
and psychosis) (18.5%), serositis (17.3%) and discoid 
rash (14.8%).
There was no significant correlation between the 
SLE initial manifestations, laboratory findings and dif-
ferent alleles of the p53 gene (p > 0.05). However, there 
were significant relationships between diarrhea, pulmo-
nary involvement, photosensitivity, malar rash and p53 
gene polymorphism (p < 0.05) (Table III).
Discussion
According to the findings of the present study, there 
are significant associations between the different allele 
types of p53 codon 72 and SLE in our population.
Table I. Frequency of p53 genotypes in SLE patients
Group
p53 genotype
AA PP AP Total
Control n 31 19 30 80
% 38.8 23.8 37.5 100
SLE n* 22 11 32 65
% 28.6 14.3 41.6 100
Total n 53 30 62 145
% 36.5 20.7 42.8 100
*DNA analysis was performed in 65 patients
Table II. Initial clinical manifestations of SLE patients
Initial sign Prevalence (%)
Fever 37
Arthritis 33.3
Arthralgia 28.4
Malar rash 22.2
Edema 8.6
Skin 7.4
Thrombosis 7.4
Fatigue 7.4
Seizure 7.4
Anorexia 4.9
Other 33.9
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In a study in 2005 in South Korea on 90 patients with 
SLE who were compared with 114 controls, it was found 
that proline carriers had higher risk of developing SLE 
than those with arginine [21]. However, another study 
on 513 SLE patients and 567 controls of a Spanish popu-
lation in 2006 could not find any significant association 
between codon 72 of p53 polymorphism and lupus as 
well as its clinical feature [14]. Therefore they concluded 
that p53 codon 72 polymorphism does not play an im-
portant role in the susceptibility to or severity of SLE in 
their population [14].
Our study showed no significant association be-
tween the initial manifestations of SLE as well as labo-
ratory findings and p53. In a study in Poland which was 
performed on 155 patients and 150 controls, there was 
no significant association between p53 codon 72 poly-
morphism and initial symptoms as well as the laborato-
ry findings of lupus but a weak association was reported 
between Arg/Arg genotype of p53 and lupus morbidity 
[18]. Our study found a significant association between 
p53 codon 72 polymorphism and some clinical manifes-
tations of SLE such as photosensitivity, malar rash as 
well as some morbidities including diarrhea and pulmo-
nary involvement.
A meta-analysis in 2012 that included 6 SLE studies 
showed that there is a significant association between 
the p53 C allele and SLE in Asians but not in Europeans 
[22]. They concluded that p53 codon 72 polymorphism 
could predict susceptibility to SLE only in Asians, which 
confirms our results [22].
Differences between findings of various studies may 
be due to the genetic background and environmental 
factors that influence disease susceptibility, lupus man-
ifestation and progression. 
Having no positive and negative control sample con-
firmed by sequencing was the main limitation of our 
study. 
In conclusion, according to the results of the present 
study, it seems that p53 may be a determinant factor in 
SLE susceptibility and its manifestations and morbidity 
as well.
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